PCRX

+ Watchlist + Portfolio

Pacira BioSciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $24.36
52-Week Range: $18.80 – $27.66
Market Cap: $949.91M
P/E (TTM): 68.09
EPS (TTM): 0.35
Dividend Yield: —

Advanced Metrics

Price/Book: 1.41
PEG Ratio: 11.21
Return on Equity: 2.05%
Return on Assets: 1.48%
Gross Margin: 79.21%
Operating Margin: 6.17%
Profit Margin: 1.96%
Current Ratio: 5.04
Debt/Equity: 0.61
Total Debt: $412.12M
Free Cash Flow: $98.34M
Revenue Growth: 6.20%
Earnings Growth: —
Enterprise Value: $1.11B

PCRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$666.82M	$674.98M	$700.97M	$726.41M
Cost of Revenue	$199.29M	$184.67M	$170.43M	$149.75M
Gross Profit	$467.53M	$490.31M	$530.54M	$576.66M
Research & Development	$84.80M	$76.26M	$81.58M	$117.31M
Selling, General & Admin	$254.52M	$269.44M	$294.10M	$368.76M
Operating Expenses	$407.50M	$402.63M	$440.67M	$557.47M
Operating Income	$60.02M	$87.67M	$89.87M	$19.19M
EBITDA	$140.38M	$154.59M	$29.12M	$122.50M
Pretax Income	$13.30M	$61.70M	-$63.11M	$16.87M
Income Tax	-$2.61M	$19.75M	$36.45M	$9.84M
Net Income	$15.91M	$41.95M	-$99.56M	$7.03M
Diluted EPS	0.34	0.89	-2.15	0.16
Diluted Shares	46.54M	51.98M	46.24M	45.04M

PCRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$104.14M	$153.30M	$276.77M	$158.54M
Receivables	$98.40M	$105.56M	$113.30M	$124.07M
Inventory	$96.06M	$104.35M	$125.28M	$152.86M
Current Assets	$498.33M	$509.99M	$745.13M	$547.97M
Total Assets	$1.68B	$1.57B	$1.55B	$1.26B
Current Liabilities	$147.77M	$97.38M	$309.92M	$120.59M
Long-Term Debt	$655.82M	$513.80M	$383.55M	$372.19M
Total Debt	$763.39M	$586.04M	$638.85M	$418.20M
Total Liabilities	$906.19M	$704.26M	$775.17M	$571.81M
Retained Earnings	-$148.75M	-$106.80M	-$206.36M	-$199.32M
Shareholders' Equity	$775.01M	$870.13M	$778.35M	$693.11M
Working Capital	$350.56M	$412.61M	$435.21M	$427.38M
Net Debt	$585.33M	$369.14M	$308.55M	$213.64M

PCRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$145.27M	$154.65M	$189.39M	$151.99M
Capital Expenditure	-$30.08M	-$15.16M	-$10.64M	-$15.33M
Free Cash Flow	$115.20M	$139.49M	$178.75M	$136.66M
Depreciation & Amortisation	$91.50M	$75.57M	$78.78M	$91.02M
Stock-Based Compensation	$48.09M	$47.90M	$51.17M	$57.50M
Investing Cash Flow	-$225.19M	$77.54M	-$83.28M	$99.48M
Financing Cash Flow	-$401.53M	-$183.03M	$17.36M	-$369.63M
Share Repurchases	$0.00	$0.00	-$25.00M	-$148.33M
Net Change in Cash	-$481.44M	$49.16M	$123.48M	-$118.15M

PCRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$168.92M	$181.10M	$179.52M	$196.87M	$177.38M
Cost of Revenue	$34.31M	$40.87M	$34.28M	$40.30M	$36.41M
Gross Profit	$134.62M	$140.23M	$145.24M	$156.57M	$140.96M
Research & Development	$25.34M	$28.20M	$25.97M	$37.45M	$28.07M
Selling, General & Admin	$86.78M	$88.58M	$91.80M	$101.61M	$93.94M
Operating Expenses	$126.44M	$131.10M	$132.09M	$167.50M	$136.34M
Operating Income	$8.18M	$9.13M	$13.15M	-$10.92M	$4.63M
EBITDA	$33.61M	$29.24M	$34.37M	$25.29M	$29.51M
Pretax Income	$8.71M	-$1.93M	$9.52M	$571.00K	$5.00M
Income Tax	$3.89M	$2.92M	$4.09M	-$1.07M	$2.08M
Net Income	$4.81M	-$4.85M	$5.43M	$1.64M	$2.92M
Diluted EPS	0.10	-0.11	0.12	0.04	0.07
Diluted Shares	46.53M	45.46M	44.46M	42.98M	40.91M

PCRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$283.61M	$300.48M	$147.59M	$158.54M	$144.31M
Receivables	$104.75M	$114.37M	$115.27M	$124.07M	$125.64M
Inventory	$133.75M	$148.16M	$157.68M	$152.86M	$150.37M
Current Assets	$759.96M	$745.61M	$562.75M	$547.97M	$514.96M
Total Assets	$1.59B	$1.54B	$1.30B	$1.26B	$1.21B
Current Liabilities	$314.73M	$313.16M	$107.08M	$120.59M	$108.79M
Long-Term Debt	$381.29M	$378.10M	$376.72M	$372.19M	$367.66M
Total Debt	$636.46M	$631.40M	$425.31M	$418.20M	$411.18M
Total Liabilities	$788.13M	$779.50M	$570.36M	$571.81M	$554.64M
Retained Earnings	-$201.54M	-$206.39M	-$200.96M	-$199.32M	-$196.41M
Shareholders' Equity	$798.54M	$757.77M	$727.21M	$693.11M	$653.89M
Working Capital	$445.23M	$432.45M	$455.67M	$427.38M	$406.17M
Net Debt	$299.77M	$280.01M	$229.13M	$213.64M	$223.35M

PCRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$35.46M	$12.01M	$60.83M	$43.69M	$25.68M
Capital Expenditure	-$8.55M	-$2.70M	-$3.87M	-$218.00K	-$2.72M
Free Cash Flow	$26.91M	$9.31M	$56.96M	$43.47M	$22.96M
Depreciation & Amortisation	$21.17M	$27.32M	$21.19M	$21.34M	$21.33M
Stock-Based Compensation	$14.55M	$15.47M	$13.98M	$13.50M	$13.54M
Investing Cash Flow	-$25.63M	$62.16M	$43.61M	$19.33M	$19.44M
Financing Cash Flow	-$2.99M	-$57.51M	-$257.48M	-$51.65M	-$59.40M
Share Repurchases	$0.00	-$50.04M	-$50.04M	-$48.25M	-$50.05M
Net Change in Cash	$6.84M	$16.67M	-$153.03M	$11.37M	-$14.28M

Market Snapshot

About

Pacira BioSciences is a commercial-stage pharmaceutical company focused on non-opioid pain management and regenerative health solutions. The company markets EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic used in surgical settings to manage post-operative pain. Pacira also offers ZILRETTA for osteoarthritis knee pain and iovera° for peripheral nerve treatment. The company is committed to advancing non-opioid alternatives to help reduce opioid use and is headquartered in Parsippany, New Jersey.